Exploring the Interface Between Idiopathic Exploring the Regulatory Considerations for Clinical Trial Design when Evaluating Treatments for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis
Time: 12:00 pm
day: Day Two Track B AM
Details:
• With the evolution of the field and new combinatory approach should we be looking at IPF and PPF in the same light?
• What are the regulatory distinctions for IPF and PPF trial design? Should these be pursued as separate indications and run in parallel?
• Is clinical design a cut and paste entity from IPF trials or are there special considerations to navigate potential pitfalls?
